Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/4/577 |
| _version_ | 1797603872343064576 |
|---|---|
| author | Niki Katsiki Michal Vrablik Maciej Banach Ioanna Gouni-Berthold |
| author_facet | Niki Katsiki Michal Vrablik Maciej Banach Ioanna Gouni-Berthold |
| author_sort | Niki Katsiki |
| collection | DOAJ |
| description | Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Apart from the two available anti-PCSK9 monoclonal antibodies (alirocumab and evolocumab), other nucleic acid-based therapies that inhibit or “silence” the expression of PCSK9 are being developed. Among them, inclisiran is the first-in-class small interfering RNA (siRNA) against PCSK9 that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. Importantly, inclisiran therapy may improve low-density lipoprotein cholesterol (LDL-C) target achievement by offering a prolonged and significant LDL-C-lowering effect with the administration of only two doses per year. The present narrative review discusses the <b>ORION/VICTORION</b> clinical trial program that has been designed to investigate the impact of inclisiran on atherogenic lipoproteins and major adverse cardiac events in different patient populations. The results of the completed clinical trials are presented, focusing on the effects of inclisiran on LDL-C and lipoprotein (a) (Lp(a)) levels as well as on other lipid parameters such as apolipoprotein B and non-high-density lipoprotein cholesterol (non-HDL-C). Ongoing clinical trials with inclisiran are also discussed. |
| first_indexed | 2024-03-11T04:39:13Z |
| format | Article |
| id | doaj.art-4fc927d3b68b4dbb931c05e71e9b4a55 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T04:39:13Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-4fc927d3b68b4dbb931c05e71e9b4a552023-11-17T20:50:54ZengMDPI AGPharmaceuticals1424-82472023-04-0116457710.3390/ph16040577Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)Niki Katsiki0Michal Vrablik1Maciej Banach2Ioanna Gouni-Berthold3Department of Nutritional Sciences and Dietetics, International Hellenic University, 574 00 Thessaloniki, GreeceThird Department of Medicine-Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech RepublicDepartment of Preventive Cardiology and Lipidology, Medical University of Lodz and Polish Mother’s Memorial Hospital Research Institute, 93-338 Lodz, PolandCenter for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, GermanyDyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Apart from the two available anti-PCSK9 monoclonal antibodies (alirocumab and evolocumab), other nucleic acid-based therapies that inhibit or “silence” the expression of PCSK9 are being developed. Among them, inclisiran is the first-in-class small interfering RNA (siRNA) against PCSK9 that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. Importantly, inclisiran therapy may improve low-density lipoprotein cholesterol (LDL-C) target achievement by offering a prolonged and significant LDL-C-lowering effect with the administration of only two doses per year. The present narrative review discusses the <b>ORION/VICTORION</b> clinical trial program that has been designed to investigate the impact of inclisiran on atherogenic lipoproteins and major adverse cardiac events in different patient populations. The results of the completed clinical trials are presented, focusing on the effects of inclisiran on LDL-C and lipoprotein (a) (Lp(a)) levels as well as on other lipid parameters such as apolipoprotein B and non-high-density lipoprotein cholesterol (non-HDL-C). Ongoing clinical trials with inclisiran are also discussed.https://www.mdpi.com/1424-8247/16/4/577inclisiranatherosclerotic cardiovascular diseaseproprotein convertase subtilisin/kexin type 9 inhibitorlow-density lipoprotein cholesterollipoprotein (a) |
| spellingShingle | Niki Katsiki Michal Vrablik Maciej Banach Ioanna Gouni-Berthold Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) Pharmaceuticals inclisiran atherosclerotic cardiovascular disease proprotein convertase subtilisin/kexin type 9 inhibitor low-density lipoprotein cholesterol lipoprotein (a) |
| title | Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) |
| title_full | Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) |
| title_fullStr | Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) |
| title_full_unstemmed | Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) |
| title_short | Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) |
| title_sort | inclisiran low density lipoprotein cholesterol and lipoprotein a |
| topic | inclisiran atherosclerotic cardiovascular disease proprotein convertase subtilisin/kexin type 9 inhibitor low-density lipoprotein cholesterol lipoprotein (a) |
| url | https://www.mdpi.com/1424-8247/16/4/577 |
| work_keys_str_mv | AT nikikatsiki inclisiranlowdensitylipoproteincholesterolandlipoproteina AT michalvrablik inclisiranlowdensitylipoproteincholesterolandlipoproteina AT maciejbanach inclisiranlowdensitylipoproteincholesterolandlipoproteina AT ioannagouniberthold inclisiranlowdensitylipoproteincholesterolandlipoproteina |